Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 35: 1447-1451, 1989;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gimsing, P.
Right arrow Articles by Nexo, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gimsing, P.
Right arrow Articles by Nexo, E.

Clinical Chemistry, Vol 35, 1447-1451, Copyright © 1989 by American Association for Clinical Chemistry

Cobalamin-binding capacity of haptocorrin and transcobalamin: age- correlated reference intervals and values from patients

P Gimsing and E Nexo
Department of Internal Medicine and Hematology, Gentofte Hospital, Hillerod, Denmark.

Unsaturated cobalamin-binding capacity in plasma (P-UBBC) is determined by use of a silica gel (QUSO G32) to separate haptocorrin (P-ApoHC) and transcobalamin (P-ApoTC). The method is sensitive and precise: detection limit 13 pmol/L, interassay coefficients of variation 3% for P-UBBC (mean = 1080 pmol/L), 4% for P-ApoTC (mean = 700 pmol/L) (n = 30). Values for P-UBBC, P-ApoHC, P-ApoTC, and P-TBBC (P-UBBC plus P- cobalamin) determined in a population study of 228 individuals, ages 21- 87 years, did not differ by sex. These values increased with age, whereas the cobalamin saturation (P-cobalamin as percentage of P-TBBC) decreased with age. However, these changes were statistically significant but marginal and thus not clinically important. We therefore suggest using combined reference intervals (central 95 percentiles) for all age groups: 500-1200 pmol/L for P-UBBC, 90-275 pmol/L for P-ApoHC, 400-930 pmol/L for P-ApoTC, 850-1600 pmol/L for P- TBBC, and 20-50% for cobalamin saturation. Results for 277 inpatients show high P-ApoHC in myeloproliferative disorders or acute nonlymphatic leukemia, whereas P-ApoTC concentrations are high in some patients with lymphoproliferative disorders or autoimmune diseases.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
R. Obeid, A. L. Morkbak, W. Munz, E. Nexo, and W. Herrmann
The Cobalamin-Binding Proteins Transcobalamin and Haptocorrin in Maternal and Cord Blood Sera at Birth
Clin. Chem., February 1, 2006; 52(2): 263 - 269.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
Z. Lloyd-Wright, A.-M. Hvas, J. Moller, T. A.B. Sanders, and E. Nexo
Holotranscobalamin as an Indicator of Dietary Vitamin B12 Deficiency
Clin. Chem., December 1, 2003; 49(12): 2076 - 2078.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
H. Zetterberg, E. Nexo, B. Regland, L. Minthon, R. Boson, M. Palmer, L. Rymo, and K. Blennow
The Transcobalamin (TC) Codon 259 Genetic Polymorphism Influences Holo-TC Concentration in Cerebrospinal Fluid from Patients with Alzheimer Disease
Clin. Chem., July 1, 2003; 49(7): 1195 - 1198.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
E. Nexo, A.-M. Hvas, O. Bleie, H. Refsum, S. N. Fedosov, S. E. Vollset, J. Schneede, J. E. Nordrehaug, P. M. Ueland, and O. K. Nygard
Holo-Transcobalamin Is an Early Marker of Changes in Cobalamin Homeostasis. A Randomized Placebo-controlled Study
Clin. Chem., October 1, 2002; 48(10): 1768 - 1771.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
E. Nexo, A.-L. Christensen, T. E. Petersen, and S. N. Fedosov
Measurement of Transcobalamin by ELISA
Clin. Chem., October 1, 2000; 46(10): 1643 - 1649.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. Holleland, J. Schneede, P. M. Ueland, P. K. Lund, H. Refsum, and S. Sandberg
Cobalamin Deficiency in General Practice. Assessment of the Diagnostic Utility and Cost-Benefit Analysis of Methylmalonic Acid Determination in Relation to Current Diagnostic Strategies
Clin. Chem., February 1, 1999; 45(2): 189 - 198.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American Association for Clinical Chemistry.